person · Reporting owner
Myszkowski Kenneth Allen
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Chief Financial Officer | January 04, 2025 | January 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date January 04, 2025 · Filed January 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500,600 |
Reported balance
After 2025-01-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-04 · Grant · Acquired 100,000 · Balance 500,600 F1: Represents shares underlying restricted stock units with a grant date 01/04/2025, which will vest in four equal annual installments. |
| Common StockSEC Table I · non-derivative | Direct | 482,835 |
Reported balance
After 2025-01-06 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-01-06 · Sale · Disposed 17,765 · Balance 482,835 F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.18 to $20.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Partial disposition of RSUs to satisfy tax withholding obligations. F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| Common StockSEC Table I · non-derivative | Direct | 473,433 |
Reported balance
After 2025-01-06 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-01-06 · Sale · Disposed 9,402 · Balance 473,433 F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Partial disposition of RSUs to satisfy tax withholding obligations. F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| Common StockSEC Table I · non-derivative | Direct | 465,433 |
Reported balance
After 2025-01-07 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2025-01-07 · Sale · Disposed 8,000 · Balance 465,433 F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 19.64 to $ 19.79, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Partial disposition of RSUs to satisfy tax withholding obligations. F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| Common StockSEC Table I · non-derivative | Direct | 455,433 |
Reported balance
After 2025-01-07 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2025-01-07 · Sale · Disposed 10,000 · Balance 455,433 F8: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.62 to $19.78, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying restricted stock units with a grant date 01/04/2025, which will vest in four equal annual installments.
F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3: Partial disposition of RSUs to satisfy tax withholding obligations.
F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.18 to $20.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F7: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 19.64 to $ 19.79, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F8: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.62 to $19.78, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2025 Filed Jan 8, 2025 02:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 10,000 | $19.69 | $196,900.00 |
DisclosureSEC source: 0001628280-25-000805 · wk-form4_1736303271.xml · nonDerivative · entry 5 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,433 F8 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.62 to $19.78, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 07, 2025 Filed Jan 8, 2025 02:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 8,000 | $19.70 | $157,600.00 |
DisclosureSEC source: 0001628280-25-000805 · wk-form4_1736303271.xml · nonDerivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 465,433 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 19.64 to $ 19.79, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 02:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 9,402 | $20.10 | $188,980.20 |
DisclosureSEC source: 0001628280-25-000805 · wk-form4_1736303271.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 473,433 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 02:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 17,765 | $19.68 | $349,615.20 |
DisclosureSEC source: 0001628280-25-000805 · wk-form4_1736303271.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 482,835 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.18 to $20.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 04, 2025 Filed Jan 8, 2025 02:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-000805 · wk-form4_1736303271.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 500,600 F1 · shares: Represents shares underlying restricted stock units with a grant date 01/04/2025, which will vest in four equal annual installments. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:54 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 40,000 | $35.19 | $1,407,600.00 |
DisclosureSEC source: 0001628280-24-010062 · wk-form4_1709938483.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,600 F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 35.00 to $35.53, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 22:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 8,904 | $35.65 | $317,427.60 |
DisclosureSEC source: 0001628280-24-000866 · wk-form4_1704752198.xml · nonDerivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 440,600 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.51 to $35.93, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 22:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,800 | $34.97 | $202,826.00 |
DisclosureSEC source: 0001628280-24-000866 · wk-form4_1704752198.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 449,504 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $34.48 to $35.42, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 22:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,400 | $34.04 | $47,656.00 |
DisclosureSEC source: 0001628280-24-000866 · wk-form4_1704752198.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,304 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.46 to $34.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 22:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-000866 · wk-form4_1704752198.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,704 F1 · shares: Represents shares underlying restricted stock units with a grant date 01/04/24, which will vest in four equal annual installments. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 22:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 15,000 | $36.20 | $543,000.00 |
DisclosureSEC source: 0001628280-23-023950 · wf-form4_168807847193372.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,704 F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $36.08 to $36.26, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 00:14 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002116 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,704 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments, with a commencement date of 1/4/23. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 29, 2022 Filed Dec 30, 2022 22:12 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 30,625 | $40.00 | $1,225,000.00 |
DisclosureSEC source: 0001209191-22-063020 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,704 F1 · shares: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| June 15, 2022 Filed Sep 30, 2022 21:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 96,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051673 · doc5.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,329 F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,786 | $63.95 | $242,114.70 |
DisclosureSEC source: 0001209191-22-002290 · doc4.xml · nonDerivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,005 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.82 to $64.35, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F6 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,778 | $63.17 | $238,656.26 |
DisclosureSEC source: 0001209191-22-002290 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,791 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.69 to $63.69, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 16,528 | $62.00 | $1,024,736.00 |
DisclosureSEC source: 0001209191-22-002290 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471,569 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.63 to $62.63, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 01:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 15,908 | $60.50 | $962,434.00 |
DisclosureSEC source: 0001209191-22-002290 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,097 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.11 to $61.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:25 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001299 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,005 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 12, 2021 Filed Jan 12, 2021 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,441 | $81.00 | $116,721.00 |
DisclosureSEC source: 0001209191-21-003295 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,005 Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 11,597 | $81.02 | $939,588.94 |
DisclosureSEC source: 0001209191-21-003295 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,446 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 23:08 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 25,166 | $72.63 | $1,827,806.58 |
DisclosureSEC source: 0001209191-21-002577 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,043 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.20 to $72.87, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 23:08 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 4,359 | $71.77 | $312,845.43 |
DisclosureSEC source: 0001209191-21-002577 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,209 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.19 to $72.17, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 23:08 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,100 | $70.75 | $77,825.00 |
DisclosureSEC source: 0001209191-21-002577 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,568 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.11 to $71.11, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:20 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001555 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,668 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:49 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 43,505 | $0.00 Strike: $14.54 | $0.00 |
DisclosureSEC source: 0001209191-20-058075 · doc4.xml · derivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,505 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:49 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 17,665 | $69.86 | $1,234,076.90 |
DisclosureSEC source: 0001209191-20-058075 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,668 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.51 to $70.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:49 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 25,840 | $69.04 | $1,783,993.60 |
DisclosureSEC source: 0001209191-20-058075 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,333 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $69.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:49 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 43,505 | $14.54 | $632,562.70 |
DisclosureSEC source: 0001209191-20-058075 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 22:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 29,166 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-20-055599 · doc4.xml · derivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,505 Underlying: Common Stock · 29,166 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 22:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 29,166 | $54.04 | $1,576,130.64 |
DisclosureSEC source: 0001209191-20-055599 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,668 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.00 to $54.07, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 22:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 29,166 | $6.15 | $179,370.90 |
DisclosureSEC source: 0001209191-20-055599 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 10,834 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-20-013488 · doc4.xml · derivative · entry 10 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,671 Underlying: Common Stock · 10,834 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 12,116 | $0.00 Strike: $7.75 | $0.00 |
DisclosureSEC source: 0001209191-20-013488 · doc4.xml · derivative · entry 9 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,505 Underlying: Common Stock · 12,116 shares Expires 2025-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 6,495 | $0.00 Strike: $14.54 | $0.00 |
DisclosureSEC source: 0001209191-20-013488 · doc4.xml · derivative · entry 8 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,621 Underlying: Common Stock · 6,495 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-20-013488 · doc4.xml · derivative · entry 7 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,116 Underlying: Common Stock · 2,000 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $9.90 | $0.00 |
DisclosureSEC source: 0001209191-20-013488 · doc4.xml · derivative · entry 6 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,116 Underlying: Common Stock · 12,000 shares Expires 2020-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 10,834 | $6.15 | $66,629.10 |
DisclosureSEC source: 0001209191-20-013488 · doc4.xml · nonDerivative · entry 5 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 12,116 | $7.75 | $93,899.00 |
DisclosureSEC source: 0001209191-20-013488 · doc4.xml · nonDerivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 6,495 | $14.54 | $94,437.30 |
DisclosureSEC source: 0001209191-20-013488 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 2,000 | $5.19 | $10,380.00 |
DisclosureSEC source: 0001209191-20-013488 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 12,000 | $9.90 | $118,800.00 |
DisclosureSEC source: 0001209191-20-013488 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 23:15 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 33,351 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-20-004722 · doc4.xml · derivative · entry 8 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,116 Underlying: Common Stock · 33,351 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 23:15 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,450 | $52.13 | $179,848.50 |
DisclosureSEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 7 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,223 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.70 to $52.39, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 23:15 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 10,680 | $51.11 | $545,854.80 |
DisclosureSEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 6 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,673 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.67 to $51.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 23:15 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,800 | $49.98 | $139,944.00 |
DisclosureSEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 5 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,353 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.64 to $50.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 23:15 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 10,554 | $49.07 | $517,884.78 |
DisclosureSEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,153 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.62 to $49.62, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 23:15 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 6,432 | $47.93 | $308,285.76 |
DisclosureSEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,707 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.60 to $48.60, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 23:15 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 6,397 | $47.07 | $301,106.79 |
DisclosureSEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,139 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.58 to $47.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 23:15 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 33,351 | $5.19 | $173,091.69 |
DisclosureSEC source: 0001209191-20-004722 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.